A study of Thalidomide, Bendamustine, and Dexamethasone (BTD) vs Bortezomib, Bendamustine, and Dexamethasone (BBD) in patients with renal failure defined as a GFR below 30 mls/min
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2019
Price : $35 *
At a glance
- Drugs Bendamustine (Primary) ; Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone; Thalidomide
- Indications Myeloma
- Focus Pharmacodynamics
- Acronyms OPTIMAL
- Sponsors Janssen-Cilag
- 02 Jul 2019 Planned End Date changed from 1 Jun 2020 to 31 Jul 2020.
- 29 Apr 2019 Status changed from completed to active, no longer recruiting.
- 10 May 2018 Planned End Date changed from 1 Apr 2018 to 1 Jun 2019.